Teva Hit by Increased Competition in U.S. Generics

Teva warned of the rapid deterioration of its U.S. generics business, prompting the Israel-based drugmaker to look at cutting costs and considering divestitures.

from WSJ.com: US Business http://ift.tt/2v0zEEG
via IFTTT